Effect of live weight pre- and post-lambing on milk production of East Friesian sheep

The study was conducted to analyse the effect of sheep body weight (BW) at mating, mid-pregnancy, lambing, early lactation, mid-lactation and late lactation on milk yield and patterns of milk production. Also, the effects of environmental factors such as number of lambing (NL) and type of lambing (TL) on BW and milk production were analysed. A total of 52 multiparous East Friesian ewes from an experimental flock were used. Ewes were assigned to three different groups according to their BW at each productive stage: low (LBW), moderate (MBW) and high BW (HBW). Lactations were fitted using the mechanistic model described by Pollott. Total milk yield (TMY), peak yield (PY) and time at peak yield (TPY) were also calculated. HBW ewes had consistently higher TMY (p < .001) and PY (p < .05) values, than LBW and MBW in most of productive stage measured. There was a positive linear relationship (p < .05) between TMY and BW in all-productive stage, except at mid-gestation where the relationship was quadratic. HBW ewes weighted at mid-pregnancy showed the highest values of maximum secretion parameter (p = .04) of Pollott model, which could partially explain the better milk yield of HBW ewes. A significant effect of NL on BW (p = .007) and TMY (p = .007) was observed. The BW ewe’s in pregnancy and early lactation is a useful indicator at farm level to improve the milk yield performance in dairy sheep

Procesos de diálogo para la formulación de políticas de CTI en América Latina y España

Este trabajo forma parte de un esfuerzo más amplia de reflexión sobre Ciencia, Tecnología y Sociedad en América Latina, que viene desarrollando el Grupo de trabajo Ciencia y Sociedad de CLACSO. En particular, este libro contribuye a alimentar el pensamiento en torno a la generación de políticas de CTI basadas en la evidencia, a partir de la discusión de estudios de caso sobre los procesos de diálogo de las comunidades para construir política pública. Esperamos que la recopilación de estos casos de estudios, estructurados a través del marco analítico que proponemos, sean considerados como un aporte a la construcción de políticas públicas de CTI, basadas en la participación pública, que logren contribuir al desarrollo de ALC y España. De la Presentación de Gabriela Dutrénit y José Miguel Natera

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Background: Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurrent stroke compared with antiplatelet therapy. We hypothesised that anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, would reduce the risk of recurrent ischaemic stroke compared with aspirin among patients with PFO enrolled in the NAVIGATE ESUS trial. Methods: NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS. For this prespecified subgroup analysis, cohorts with and without PFO were defined on the basis of transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE). The primary efficacy outcome was time to recurrent ischaemic stroke between treatment groups. The primary safety outcome was major bleeding, according to the criteria of the International Society of Thrombosis and Haemostasis. The primary analyses were based on the intention-to-treat population. Additionally, we did a systematic review and random-effects meta-analysis of studies in which patients with cryptogenic stroke and PFO were randomly assigned to receive anticoagulant or antiplatelet therapy. Findings: Between Dec 23, 2014, and Sept 20, 2017, 7213 participants were enrolled and assigned to receive rivaroxaban (n=3609) or aspirin (n=3604). Patients were followed up for a mean of 11 months because of early trial termination. PFO was reported as present in 534 (7·4%) patients on the basis of either TTE or TOE. Patients with PFO assigned to receive aspirin had a recurrent ischaemic stroke rate of 4·8 events per 100 person-years compared with 2·6 events per 100 person-years in those treated with rivaroxaban. Among patients with known PFO, there was insufficient evidence to support a difference in risk of recurrent ischaemic stroke between rivaroxaban and aspirin (hazard ratio [HR] 0·54; 95% CI 0·22–1·36), and the risk was similar for those without known PFO (1·06; 0·84–1·33; pinteraction=0·18). The risks of major bleeding with rivaroxaban versus aspirin were similar in patients with PFO detected (HR 2·05; 95% CI 0·51–8·18) and in those without PFO detected (HR 2·82; 95% CI 1·69–4·70; pinteraction=0·68). The random-effects meta-analysis combined data from NAVIGATE ESUS with data from two previous trials (PICSS and CLOSE) and yielded a summary odds ratio of 0·48 (95% CI 0·24–0·96; p=0·04) for ischaemic stroke in favour of anticoagulation, without evidence of heterogeneity. Interpretation: Among patients with ESUS who have PFO, anticoagulation might reduce the risk of recurrent stroke by about half, although substantial imprecision remains. Dedicated trials of anticoagulation versus antiplatelet therapy or PFO closure, or both, are warranted. Funding: Bayer and Janssen

Revista Temas Agrarios Volumen 26; Suplemento 1 de 2021

1st International and 2nd National Symposium of Agronomic Sciences: The rebirth of the scientific discussion space for the Colombian Agro.1 Simposio Intenacional y 2 Nacional de Ciencias Agronómicas: El renacer del espacio de discusión científica para el Agro colombiano

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

International audienceSignificance There is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It is important to estimate their quantitative impact on COVID-19 mortality upon SARS-CoV-2 infection, by age and sex, as both the prevalence of these autoantibodies and the risk of COVID-19 death increase with age and are higher in men. Using an unvaccinated sample of 1,261 deceased patients and 34,159 individuals from the general population, we found that autoantibodies against type I IFNs strongly increased the SARS-CoV-2 infection fatality rate at all ages, in both men and women. Autoantibodies against type I IFNs are strong and common predictors of life-threatening COVID-19. Testing for these autoantibodies should be considered in the general population

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

International audienceSignificance There is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It is important to estimate their quantitative impact on COVID-19 mortality upon SARS-CoV-2 infection, by age and sex, as both the prevalence of these autoantibodies and the risk of COVID-19 death increase with age and are higher in men. Using an unvaccinated sample of 1,261 deceased patients and 34,159 individuals from the general population, we found that autoantibodies against type I IFNs strongly increased the SARS-CoV-2 infection fatality rate at all ages, in both men and women. Autoantibodies against type I IFNs are strong and common predictors of life-threatening COVID-19. Testing for these autoantibodies should be considered in the general population